Nuvalent
phase population heavily solid tumors | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
October 2023
Slide
17 of 52
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
patient population heavily solid tumors phase characteristic age median range female tumor type pancreatic adenocarcinoma non smoker history of metastases measurable lesions all treated data as of for patients treated by all data shown as unless otherwise specified central nervous system eastern oncology group performance status non smell lung cancer response evaluation criteria in version tyrosine kinase includes patients with untreated lesions categories are not mutually exclusive source a treatment prior lines of anticancer treatment median range prior treatments without chemotherapy and chemotherapy without chemotherapy and received chemotherapy and other all treated an i | Nuvalent
Investor Presentation
April 2024
patient population heavily alk solid tumors phase characteristic age median range female non smoker tumor type pancreatic adenocarcinoma atypical carcinoid lung history of metastases fusion secondary mutation single mutation compound i mutations single or compound all treated data cut me all data shown as unless otherwise generation eastern coop response in performance non small version ase inhibit patients lesions not confirmed in all cases categories are not mutually exclusive source lin treatment history prior lines of anticancer treatment median range prior treatments chemotherapy received any or including and including and all treated | Nuvalent
Investor Presentation
February 2024
patient population heavily solid tumors phase characteristic age median range female tumor type pancreatic adenocarcinoma non smoker history of metastases measurable lesions punted data as of for patients treated by all data shown as unless otherwise specified central nervous system eastern oncology group performance status non lung cancer response evaluation criteria in version tyrosine kinase includes patients with untreated lesions categories are not mutually exclusive source a treatment prior lines of anticancer treatment median range prior treatments without chemotherapy and chemotherapy without chemotherapy and chemotherapy received other cee | Nuvalent
Investor Presentation
February 2024
patient population heavily alk solid tumors phase characteristic age median range female non smoker tumor type pancreatic adenocarcinoma atypical carcinoid lung history of metastases fusion secondary mutation single mutation compound i mutations single or compound data cut off unless otherwise specified east generation performance status non small cell all treated response version tyrosine kinase inhibitor pat lesions not confirmed in all cases categories are not ally source lin treatment history prior lines of anticancer treatment median range prior treatments chemotherapy received any or including and including and all treated i | Nuvalent
Related slides by other companies
SentiBio
SPAC
October 2021
gene circuit enabled pipeline with additional collaboration opportunities | SentiBio
AstraZeneca
Results
November 2024
inhibitor solid | AstraZeneca
AstraZeneca
Results
November 2024
solid | AstraZeneca
BioAtla
Investor Presentation
January 2024
phase cab demographics characteristics | BioAtla
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights